PhaseBio Pharmaceuticals, Inc. (PHASQ)

Market Cap	49.00
Revenue (ttm)	818,000
Net Income (ttm)	27.84M
Shares Out	n/a
EPS (ttm)	0.59
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	76
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	n/a
Beta	2.08
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 22, 2023

About PHASQ

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary art...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 18, 2018
• Employees: 60
• Stock Exchange: OTCMKTS
• Ticker Symbol: PHASQ

Financial Performance

In 2021, PHASQ's revenue was $10,831, a decrease of -96.62% compared to the previous year's $320,000. Losses were -$131,071, -99.87% less than in 2020.